Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study

Inclusion Criteria: * 1\. Patients receiving \*\*monotherapy with any chemotherapeutic agent\*\* (including but not limited to): * \*Alkylating agents\*: Cyclophosphamide, Carmustine, Lomustine, Temozolomide, etc. * \*Antimetabolites\*: 5-Fluorouracil, Methotrexate, Capecitabine, Gemcitabine, etc. * \*Platinum-based drugs\*: Cisplatin, Carboplatin, Oxaliplatin, etc. * \*Taxanes\*: Paclitaxel, Docetaxel, etc. * \*Anthracyclines\*: Doxorubicin, Epirubicin, etc. * \*Other agents\*: Vincristine, Etoposide, Irinotecan, etc. * and\*\* meeting all subconditions\*\*: * No concurrent use of other therapeutic drugs * Histologically confirmed malignant tumor (excluding central nervous system tumors) requiring chemotherapy * Availability of tissue biopsy results 2\. Full comprehension of the study's purpose, potential adverse reactions, and provision of \*\*written informed consent\*\*. 3\. Aged \*\*35-80 years\*\*, fluent in Chinese, cognitively capable of completing questionnaires independently, \*\*with caregiver assistance\*\* for questionnaire completion. 4\. Initial complaint of cognitive impairment (memory and/or other domains) \*\*occurring ≥3 months before chemotherapy initiation\*\*. 5\. Completion of cancer treatment with \*\*curative intent\*\* (excluding post-chemotherapy endocrine therapy). 6\. \*\*Clinical Dementia Rating (CDR)\*\* global score of \*\*0.5-2\*\* (indicating questionable to moderate cognitive impairment) and \*\*no significant visual or auditory deficits Exclusion Criteria: * 1\. Established diagnosis of \*\*cognitive impairment disorders\*\* (e.g., Alzheimer's disease, frontotemporal dementia, Parkinson's dementia). 2\. Primary or metastatic \*\*central nervous system malignancies\*\*. 3. History of \*\*brain metastases or other intracranial tumors\*\*. 4. Severe \*\*head trauma\*\* or stroke with significant residual deficits (\*\*Activities of Daily Living \[ADL\] score \< 60\*\*). 5\. Poorly controlled \*\*epilepsy\*\* or other seizure disorders. 6. \*\*Contraindications to MRI\*\* (e.g., claustrophobia, cardiac pacemakers, metal implants) - \*excluded from fMRI testing only\*; otherwise eligible participants may enroll without fMRI. 7\. Current use of \*\*cognition-affecting medications\*\*, including but not limited to: * \*Cholinesterase inhibitors\*: Donepezil, Rivastigmine, Galantamine * \*NMDA receptor antagonists\*: Memantine * \*Other agents\*: Sodium oligomannate, Ginkgo biloba extract, Oxiracetam, Piracetam, Nicergoline, Lecanemab, Aducanumab 8. \*\*Pregnancy\*\*, lactation, or plans for pregnancy. 9. Active \*\*neurological or untreated/unremitted psychiatric disorders\*\* (e.g., active major depressive disorder per DSM-5; \*stable treated depression permitted\*). 10\. \*\*Alcohol/substance abuse or dependence\*\* within the past 2 years. 11. \*\*Clinically significant systemic diseases/unstable medical conditions\*\*, including: * Cardiac: Myocardial infarction (≤1 year), unstable angina, congestive heart failure, or clinically abnormal ECG * Pulmonary: Acute asthma exacerbation, pulmonary embolism * Gastrointestinal: Active bleeding, inflammatory bowel disease * Hepatic: Cirrhosis or ALT/AST \>2× ULN * Renal: Serum creatinine \>1.5× ULN 12. Use of \*\*non-study cognition-enhancing drugs\*\* within 4 weeks prior to enrollment. 13\. Use of edaravone dexborneol within 30 days prior to enrollment.